Follow
Bert van der Vegt
Bert van der Vegt
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Verified email at umcg.nl - Homepage
Title
Cited by
Cited by
Year
Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
SQ Qiu, SJH Waaijer, MC Zwager, EGE de Vries, B van der Vegt, ...
Cancer treatment reviews 70, 178-189, 2018
4022018
Heart failure stimulates tumor growth by circulating factors
WC Meijers, M Maglione, SJL Bakker, R Oberhuber, LM Kieneker, ...
Circulation 138 (7), 678-691, 2018
2852018
Tumor-specific uptake of fluorescent bevacizumab–IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study
LE Lamberts, M Koch, JS de Jong, ALL Adams, J Glatz, MEG Kranendonk, ...
Clinical Cancer Research 23 (11), 2730-2741, 2017
2722017
cGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers
C Hong, M Schubert, AE Tijhuis, M Requesens, M Roorda, ...
Nature 607 (7918), 366-373, 2022
1672022
Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery
FJ Voskuil, PJ Steinkamp, T Zhao, B van der Vegt, M Koller, JJ Doff, ...
Nature communications 11 (1), 3257, 2020
1342020
Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers
M Koller, SQ Qiu, MD Linssen, L Jansen, W Kelder, J de Vries, I Kruithof, ...
Nature communications 9 (1), 3739, 2018
1322018
89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
F Bensch, AH Brouwers, MN Lub-de Hooge, JR de Jong, B van der Vegt, ...
European journal of nuclear medicine and molecular imaging 45, 2300-2306, 2018
1282018
Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment
K Delli, EA Haacke, FGM Kroese, RP Pollard, S Ihrler, B van der Vegt, ...
Annals of the Rheumatic Diseases 75 (11), 1933-1938, 2016
1142016
Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)
JF van Nimwegen, E Mossel, GS van Zuiden, RF Wijnsma, K Delli, AJ Stel, ...
The Lancet Rheumatology 2 (3), e153-e163, 2020
942020
Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement
T Koopman, HJ Buikema, H Hollema, GH de Bock, B van der Vegt
Breast cancer research and treatment 169, 33-42, 2018
932018
Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren’s syndrome are not predictive for parotid MALT lymphoma development
EA Haacke, B van der Vegt, A Vissink, FKL Spijkervet, H Bootsma, ...
Annals of the rheumatic diseases 76 (10), 1781-1784, 2017
922017
Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration
SCY Leung, TO Nielsen, LA Zabaglo, I Arun, SS Badve, AL Bane, ...
Histopathology 75 (2), 225-235, 2019
902019
Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: a quantitative dose-escalation study
FJ Voskuil, SJ de Jongh, WTR Hooghiemstra, MD Linssen, PJ Steinkamp, ...
Theranostics 10 (9), 3994, 2020
892020
B cell depletion therapy normalizes circulating follicular Th cells in primary Sjögren syndrome
GM Verstappen, FGM Kroese, PM Meiners, OB Corneth, MG Huitema, ...
The Journal of rheumatology 44 (1), 49-58, 2017
812017
Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma
H Hartog, HM Horlings, B van der Vegt, B Kreike, A Ajouaou, ...
Breast cancer research and treatment 129, 725-736, 2011
752011
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma
B Van Der Vegt, MAJ De Roos, JL Peterse, C Patriarca, J Hilkens, ...
Histopathology 51 (3), 322-335, 2007
742007
Imaging in primary Sjögren’s syndrome
MS van Ginkel, AWJM Glaudemans, B van der Vegt, E Mossel, ...
Journal of clinical medicine 9 (8), 2492, 2020
722020
Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies
CM Venema, LH Mammatas, CP Schröder, M van Kruchten, G Apollonio, ...
Journal of Nuclear Medicine 58 (12), 1906-1912, 2017
652017
Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast
MA de Roos, B van der Vegt, J de Vries, J Wesseling, GH de Bock
Annals of surgical oncology 14, 2097-2104, 2007
622007
p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast
MA de Roos, GH de Bock, J de Vries, B van der Vegt, J Wesseling
Journal of Surgical Research 140 (1), 109-114, 2007
612007
The system can't perform the operation now. Try again later.
Articles 1–20